Biogen's most recent trend suggests a bearish bias. One trading opportunity on Biogen is a Bear Call Spread using a strike $235.00 short call and a strike $245.00 long call offers a potential 23.46% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $235.00 by expiration. The full premium credit of $1.90 would be kept by the premium seller. The risk of $8.10 would be incurred if the stock rose above the $245.00 long call strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Biogen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Biogen is bullish.
The RSI indicator is at 45.09 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Biogen
Better Buy: Biogen vs. AbbVie
Mon, 22 Apr 2019 21:00:00 +0000
These two drug stocks have been the industry's biggest losers this year. Which is the better buy now?
Health-care earnings: ‘Medicare for all’ expected to loom large
Mon, 22 Apr 2019 18:53:00 +0000
Health-care earnings begin in earnest this week, starting with Centene Corp. reporting on Tuesday, followed by Anthem Inc., Biogen Inc., Boston Scientific Corp. and Novartis AG reporting Wednesday.
Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?
Mon, 22 Apr 2019 14:17:02 +0000
While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.
Will Bristol-Myers (BMY) Disappoint This Earnings Season?
Mon, 22 Apr 2019 12:30:12 +0000
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
Patients living with Spinal Muscular Atrophy (SMA) in the province of Saskatchewan gain access to SPINRAZA™ (nusinersen)
Mon, 22 Apr 2019 11:00:00 +0000
MISSISSAUGA, ON , April 22, 2019 /CNW/ – Biogen Canada welcomes the decision made by the Government of Saskatchewan allowing patients living with Spinal Muscular Atrophy (SMA) to access SPINRAZA™(nusinersen), the first and only approved medicine in the world to treat the root cause of SMA.
Also on Market Tamer…
Follow Us on Facebook